
Opinion|Videos|December 6, 2024
Overview of Bispecifics for R/R Multiple Myeloma
Author(s)Binod Dhakal, MD, MS
Panelist discusses how the RRMM treatment landscape has evolved significantly, with BiTEs emerging as a promising approach. BCMA-targeted BiTEs showed efficacy, while GPRC5D-targeting agents like talquetamab represent promising new options, particularly for patients with BCMA-refractory disease. Key challenges include managing cytokine release syndrome, developing optimal sequencing strategies, addressing drug resistance, and improving accessibility and affordability of novel therapies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How has the treatment landscape evolved in RRMM?
- Please elaborate on the role of bispecific T-cell engagers (BiTEs) as well as the development of BiTE targets beyond BCMAs, focusing on GPRC5D.
- What are the key unmet needs and challenges in managing patients with RRMM?
- What are the main barriers to effective treatment and optimal outcomes for this patient population?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































